About RepliCel

  
About

Overview

RepliCel is a regenerative medicine company focused on aesthetics and orthopedics. Our cell therapy products are tailor-made to restore cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. Our next-generation dermal injection technology is designed to revolutionize aesthetic treatment outcomes. RepliCel is dedicated to improving everyday lives.

Technology

RepliCel is developing several products from two unique cell therapy populations both taken from the hair follicles embedded in a small skin biopsy taken from the back of a patient's head.

RepliCel is also developing a medical device based on several patent-protected technologies related to improving patient injections.

Products

The products currently RepliCel is currently developing are:

  • RCH-01 – Cell therapy for pattern baldness
  • RCS-01 – Cell therapy for aging or sun damaged skin
  • RCT-01 – Cell therapy for tendon degeneration
  • RCI-02 – Next-generation dermal injection device

Company

RepliCel was founded on the work of two European researchers investigating the cell biology of the hair follicle: Kevin McElwee, PhD and Rolf Hoffmann, MD. RepliCel is a publicly traded company, headquarted in Canada leading the development of four products with active programs in Canada, Europe, Japan, Greater China, and the United States.

The Company is purpose-built to develop high-value assets it commercializes with established partners such as it already has in place in certain Asian countries.

RepliCel is structured to be lean and virtual by leading the development of its products through a trusted network of contract research, manufacturing, and advisors.

Executive Team

R. Lee Buckler, B. Ed, LLB

President, CEO & Director

R. Lee Buckler, B. Ed, LLB

President, CEO & Director


Mr. Buckler has been an executive in the cell therapy sector since 2000 beginning with Malachite Management in the Stem Cell Technologies group of companies. He served just over two years as Director of Business Development for Progenitor Cell Therapy prior to its acquisition by NeoStem and then Hitachi Chemical Advanced Therapeutics Solutions. Most recently he was the Managing Director of Cell Therapy Group, a consulting firm he formed in 2008.  

Mr. Buckler holds a Bachelor's Degree in Education and a Law Degree. After law school, he did a one year judicial clerkship with the B.C. Supreme Court and was a practicing attorney for three years at Edwards, Kenny & Bray. Mr. Buckler served six years as the Executive Director of the International Society for Cellular Therapy, was the inaugural chair of the Alliance for Regenerative Medicine's Communications and Education Committee, co-founded Cell Therapy News, founded Cell Therapy Blog, founded and continues to manage the LinkedIn Cell Therapy Industry Group, serves on the editorial advisory boards for the journals Regenerative Medicine and Cell and Gene Therapy Insights, and the advisory boards for Phacilitate:Exchange and RoosterBio. He is a frequent commentator, analyst, author and speaker in cell therapy.

Dr. Rolf Hoffmann, MD

Chief Medical Officer

Dr. Rolf Hoffmann, MD

Chief Medical Officer

Dr. Hoffmann is a European-based practicing dermatologist and clinical researcher who has spent decades researching the fields of pattern hair loss, alopecia areata, endocrinology of the hair follicle and hair follicle morphogenesis. Together with Dr. McElwee, he is the applicant of a landmark patent on the use of hair follicle cup cells and their use in hair diseases. He is the co-discoverer of the Company's technology and co-founder of RepliCel. He works in his private dermatology clinical practice, as a teaching professor in the Department of Dermatology for Marburg University, and as a researcher on the histopathology of hair diseases on which he has published many articles and text book chapters. 

Dr. Hoffmann has participated in dozens of clinical hair studies and consulted for a variety of large companies on hair matters. He is the inventor of TrichoScan®, a computerized technique to measure hair growth, which is part of a privately owned company which markets the device and related services for dermatologists and clinical trial researchers.

He serves as RepliCel’s Chief Medical Officer.

Dr. Kevin McElwee, PhD

Chief Scientific Officer

Dr. Kevin McElwee, PhD

Chief Scientific Officer

Dr. McElwee, co-discoverer of the Company's technology and co-founder of RepliCel, is Professor of Biomedical Sciences at the University of Bradford’s School of Chemistry and Biosciences. Previously, he as an Associate Professor in the Department of Dermatology and Skin Health at the University of British Columbia, and Director of the Hair Research Laboratory in the Vancouver Coastal Health Research Institute at Vancouver General Hospital (VGH). His research has been funded by competitive grants awarded by multiple organizations including the Canadian Institutes for Health Research (the equivalent of the National Institutes for Health in the USA). 

Dr. McElwee is one of only a small group of research scientists worldwide who studies hair biology and associated diseases. He has worked as a hair research scientist for 12 years and has published over 70 medical journal articles, research abstracts and academic book chapters on hair loss research. Dr. McElwee received his Bachelor of Science degree from the University of Aberdeen, Scotland and his PhD from the University of Dundee, Scotland. Postdoctoral training included three years at the Jackson Laboratory in Maine and four years at the University of Marburg, Germany, studying various hair loss diseases.

Dr. McElwee serves as RepliCel’s Chief Scientific Officer.

Simon Ma, CPA

Chief Financial Officer

Simon Ma, CPA

Chief Financial Officer

Mr. Ma is a Chartered Professional Accountant and has extensive experience with private and public companies. He graduated from the University of British Columbia in 1987 and obtained a degree of Bachelor of Arts in Economics after which he worked in the industry as a Controller until1990 when he started articling. He qualified as a Chartered Accountant in 1994. 

Mr. Ma has been a sole public practitioner since 1997 and is practicing under the name of Simon S. Ma Corporation. 

He is concurrently serving as chief financial officer of several public companies listed on the TSX Venture Exchange or the Canadian Securities Exchange. He was appointed RepliCel’s Director of Finance of the Company in June 2016 and as the company’s Chief Financial Officer in October 2018.


Dr. Petra Goessens-Rueck, DVM

Head of Clinical and Regulatory Affairs

Dr. Petra Goessens-Rueck, DVM

Head of Clinical and Regulatory Affairs

Dr. Goessens-Rueck has been a valuable consultant to RepliCel since its inception assisting with research, development, clinical and regulatory strategy in addition to managing regulatory submissions and most aspects of the Company's clinical trials. Dr. Goessens-Rueck is a biotech consultant with more than 10 years' in-depth experience in the development of innovative cellular therapeutics. 

She graduated with her Doctorate at the Institute of Pharmacology and Toxicology of Justus-Liebig University of Giessen, Germany in 1996, followed by a post-doctorate research fellowship with INSERM in Paris at their Department of Experimental Medicine. Her work experience includes industry leaders such as Pfizer and Ratiopharm. Since 2012, Dr. Goessens-Rueck has been recognized as one of Europe's leading consultants for advanced therapies and medicine products (ATMPs).


 

Board of Directors

David Hall

Chairman of the Board

David Hall

Chairman of the Board

Mr. Hall served as CEO and President of RepliCel Life Sciences from 2012 through 2015. He helped diversify RepliCel’s cell therapy programs from a single program to three current clinical programs, as well as the development the RCI-02 dermal injector device. Previously, Mr. Hall consulted to government, pharma industry, biotech, eHealth and NGO’s for two years. For the prior 15 years, Mr. Hall served in multiple roles including as the CFO, CCO, Treasurer and Secretary of Angiotech Pharmaceuticals Inc.

Mr. Hall is a Past Chair and board member of Life Sciences BC and current director of Providence Health Care Research Institute and VANC Pharmaceuticals. He is the author of Life Sciences BC’s position papers for the Premier’s Competition Council Report and Conversation on Health. Mr. Hall was also a member of the BC Task Force on PharmaCare and serves on the board of directors of the Advantage BC. Mr. Hall holds an Honours degree in Economics and Finance from the University of Manitoba.

Mr. Hall serves as the Chairman of RepliCel’s Board of Directors.

Geoff MacKay, BSc

Director

Geoff MacKay, BSc

Director

Mr. MacKay is an experienced biopharmaceutical executive focused in the field of regenerative medicine for the past 20 years. Mr. MacKay is currently CEO of AVROBIO Inc., a clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease. Previously, he spent 11 years as CEO of Organogenesis Inc. He is credited with helping build Organogenesis into the leading cell therapy business in the world as measured by revenue, patients treated, FDA indications and overall scale of operations. Mr. MacKay also has a strong pharma heritage, having spent 11 years at Novartis where he held senior leadership positions within the Immunology franchise in Canada, USA and at the Global office in Basel Switzerland.

Mr. MacKay has broad international experience and contacts across pharma, biotech and device industries via leadership roles within the life science industry. Examples include: Chairman of the Board of MassBio, Chairman of the Board of the Alliance of Regenerative Medicine, Advisory Council to the Health Policy Commission for Massachusetts, Deans Advisory Council Western University School of Podiatric Surgery, and Chairman of Audit Committee of the Center for Commercialization of Regenerative Medicine (C.C.R.M.).

Peter Lewis, CA

Director

Peter Lewis, CA

Director

Mr. Lewis is a chartered accountant and partner with Lewis and Company, a firm specializing in taxation law since 1993. His areas of expertise include tax planning, acquisitions and divestitures, reorganizations and estate planning. Mr. Lewis is a sought-after educator, having taught and presented taxation courses at the Institute of Chartered Accountants of British Columbia and the Canadian Tax Foundation. 

He served on the Taxation Committee of the Institute of Chartered Accountants for three years and as President and Secretary-Treasurer at the Jericho Tennis Club for a combined ten years. Mr. Lewis is currently a member of the University Endowment Lands Community Advisory Committee.

Mr. Lewis is a shareholder in RepliCel and serves as a member of the Board of Directors.

R. Lee Buckler, B. Ed, LLB

President, CEO & Director

R. Lee Buckler, B. Ed, LLB

President, CEO & Director


Mr. Buckler has been an executive in the cell therapy sector since 2000 beginning with Malachite Management in the Stem Cell Technologies group of companies. He served just over two years as Director of Business Development for Progenitor Cell Therapy prior to its acquisition by NeoStem and then Hitachi Chemical Advanced Therapeutics Solutions. Most recently he was the Managing Director of Cell Therapy Group, a consulting firm he formed in 2008.  

Mr. Buckler holds a Bachelor's Degree in Education and a Law Degree. After law school, he did a one year judicial clerkship with the B.C. Supreme Court and was a practicing attorney for three years at Edwards, Kenny & Bray. Mr. Buckler served six years as the Executive Director of the International Society for Cellular Therapy, was the inaugural chair of the Alliance for Regenerative Medicine's Communications and Education Committee, co-founded Cell Therapy News, founded Cell Therapy Blog, founded and continues to manage the LinkedIn Cell Therapy Industry Group, serves on the editorial advisory boards for the journals Regenerative Medicine and Cell and Gene Therapy Insights, and the advisory boards for Phacilitate:Exchange and RoosterBio. He is a frequent commentator, analyst, author and speaker in cell therapy.

Peter Lowry

Director

Peter Lowry

Director

Mr. Lowry is a director and consultant with Pkarma Ltd. His work includes the use of lean methodology and customer focused design, and the utilization of objective data to drive strategy and programs. Mr. Lowry’s CV includes consulting and operational management roles as General Manager of the Greenlane Heart Unit, leading Auckland Orthopedics, and the development and operational management of a number of joint-ventures that leverage intellectual property across a range of clinical and commercial settings. 

Mr. Lowry graduated with a Bachelor of Management Studies from the University of Waikato, and is a Chartered Accountant.  He is a long-term shareholder of RepliCel and served as an advisor to the Company on its transaction with YOFOTO prior to being elected to the RepliCel Board of Directors in late 2018.

Andrew Schutte

Director

Andrew Schutte

Director

Mr. Schutte is the Chief Technology Officer with MainPointe Pharmaceuticals in Louisville Kentucky. Additionally, he is president and sole proprietor of two oil industry related companies, Nolan Olbohrung LLC and Valence Oil LLC. Investment-minded and accomplished, his current CV also includes the management of several private investment accounts. 

Mr. Schutte began his career in pharmaceuticals with US based, Gerimed Inc. as a VBA Programmer. Gerimed Inc. serviced independent pharmacies serving long-term care and home care patients.  He has been a shareholder of RepliCel since early 2017 and served as an advisor to the Company prior to being elected to the RepliCel Board of Directors in late 2018.

Larissa Huang

Director

Larissa Huang

Director

Ms. Huang is the Vice President of International Business of YOFOTO Health Sciences in Greater China. She recently established a state-of-the-art physical health examination center and cell preparation centre in Ningbo, Zhejiang Province, P.R. China. In 2017, Ms. Huang was appointed head of Yofogene supervising genetic testing and multi-tumor markers.  

Ms. Huang began her health sciences career with YOFOTO managing the operations of their M&A overseas accounts and growth opportunities. Ms. Huang holds an honours degree in Economics and Politics from the University of Bristol in the United Kingdom. She was nominated by YOFOTO and elected to RepliCel’s Board of Directors in late 2018.